LETTER TO THE EDITOR

SWI/SNF alterations define a subgroup with poorer outcome among patients with aggressive forms of adult T-cell leukemia/lymphoma

Authors

Romain Loyaux,[1,2] Samy Chraibi,[3] Maïa Pesic,[1] Lucile Debus,[4] Valérie Suez-Panama,[5] Pascal Fuseau,[6] Quentin Hurlot,[6] Alina Danu,[7] Véronique Vergé,[1] Jean-Come Meniane,[4] David Ghez[7,8#] and Christophe Marzac[1#]

[1]Département de Biologie et Pathologie Médicales Gustave Roussy Université Paris-Saclay, Villejuif; [2]INSERM U1287, Université Paris-Saclay, Gustave Roussy Cancer Center, Villejuif; [3]Service d'Hématologie, Centre Universitaire de Nîmes, Nimes; [4]Service d'Hématologie, Site P. Zobda Quitman, CHU de Martinique, Fort-de-France, Martinique; [5]CHU de Martinique, Centre de Ressource Biologique de la Martinique, Fort-de-France; [6]Pôle Biologie-Pathologie, Site P. Zobda Quitman, CHU de Martinique, Fort-de-France, Martinique; [7]Département d'Hématologie, Gustave Roussy Université Paris-Saclay, Villejuif and [8]INSERM U1363, Université Paris-Saclay, Gustave Roussy Cancer Center, Villejuif, France


#DG and CM contributed equally as senior authors.


Correspondence:
D. GHEZ - david.ghez@gustaveroussy.fr
C. MARZAC - christophe.marzac@gustaveroussy.fr


https://doi.org/10.3324/haematol.2026.300706

Received: February 13, 2026.
Accepted: April 29, 2026.
Early view: May 7, 2026.


©2026 Ferrata Storti Foundation
Published under a CC BY-NC license








Supplementary Fig.1. Details and results of the sequencing strategy. (A) The sequencing strategy of the 38 samples - 33 were informative. (B) The capture-based panel of 176 genes. (C) Mean coverage of target sequencing and WES. (D) Venn diagram of variants detected by target sequencing and WES.



Supplementary Fig.2. Prevalence of co-altered mutations with SWI/SNF mutated samples (contingency with Fisher's exact test) and overall survival of principle known pejorative factors : *IRF4* (A), *TP53* (B) and *CDKN2A/B* (C).



Supplementary Fig.3.

Prevalence of the different alterations compared to other studies

(A) Prevalence of the cohort compared to Kogure Y *et al.*, Blood, 2022. (B) Prevalence of the cohort compared to Marçais A *et al.*, Leukemia, 2021